-
SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal
•
China-based SciNeuro Pharmaceuticals and Germany’s Secarna Pharmaceuticals GmbH & Co. KG have announced a research and option deal aimed at advancing treatments for central nervous system (CNS) diseases. According to the agreement, Secarna will utilize its nucleic acid discovery and development platform, LNAplus, to generate and profile antisense oligonucleotide (ASO)…
-
Beijing’s QL Bio Secures Tens of Millions in Funding for Proteomics Platform Upgrade
•
QL Bio, a Beijing-based proteomics testing company, has reportedly secured tens of millions of renminbi in its inaugural funding round, which was exclusively led by Delian Capital. The capital raised will be directed towards enhancing QL Bio’s “one-stop proteomics platform” and advancing the discovery and clinical application of protein biomarkers.…
-
ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development
•
China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for its potentially groundbreaking oncolytic virus product, MVR-C5252, which is under development to treat gliomas. This first-in-class product marks a significant step forward in the treatment of brain tumors. Global Context and PrecedenceIn June 2021, Japanese…
-
Round 8 VBP Tender Results Announced with RMB 21.6 Billion Market
•
The National Allied Procurement Office has issued an initial notification upon the completion of Round 8 of the national Volume-Based Procurement (VBP) tender program. The preliminary results, released for public comment from March 30 to April 1, 2023, indicate a market size of RMB 21.6 billion (USD 3.14 billion) based…
-
Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials
•
Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands, and Suzhou (China), has released its financial report for the period ending December 31, 2022. The company reported a total revenue of USD 40.659 million, marking an increase of 846.5% year-on-year (YOY). Research and development…
-
Janssen to Halt RSV Adult Vaccine Development, Impacting Phase III Trial
•
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary, Janssen, has announced its decision to terminate its respiratory syncytial virus (RSV) adult vaccine development program, which includes discontinuing a Phase III trial. This strategic move is a response to the current RSV vaccine landscape and is part of an effort to optimize…
-
Luye Pharma Group Reports 15% Revenue Growth in 2022 Financial Results
•
China-based Luye Pharma Group (HKG: 2186) has released its 2022 financial report, recording a total revenue of RMB 5.982 billion (USD 869.8 million), marking a 15.0% year-on-year (YOY) increase. The company’s performance reflects significant growth, particularly in its tumor treatment sector, which saw a 63.1% increase to RMB 2.306 billion…
-
Pfizer’s Ritlecitinib Heads for Priority Review in China for Vitiligo Treatment
•
The China’s Center for Drug Evaluation (CDE) website has indicated that Pfizer’s (NYSE: PFE) ritlecitinib, a Janus kinase 3 (JAK3) inhibitor, is on track for priority review status for the treatment of vitiligo in China. This development highlights the potential fast-track approval process for this novel therapy in addressing the…
